Latest resistant prostate cancer Stories
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a way to image the spread of a particularly dangerous form of prostate cancer earlier than conventional imaging in use today, which may allow oncologists to find and treat these metastases more quickly and give patients a better chance at survival.
ORLANDO, Fla., Feb. 18, 2011 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 21, 2010 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced $3 million in Convertible Note funding.
HOUSTON, Nov. 10, 2010 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc., a company developing novel therapies that can be precisely controlled after delivery, today announced the appointment of four new members to its Clinical Advisory Board (CAB).
Results Presented at ASCO 2010 Annual Meeting Confirm Acceptable Safety Profile and Evidence of Biological Activity Including Declines in Circulating Tumor Cells and Reductions in Tumor Markers BOTHELL, WA, and VANCOUVER, June 7 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc.
HOUSTON, April 19 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc., a company developing therapeutic cancer vaccines, today announced the presentation of interim Phase I/II efficacy data for BPX-101, a novel dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in a Late Breaking poster at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 held in Washington, D.C. Guru Sonpavde, M.D., Principal Investigator at The University of Texas Health...
BOTHELL, WA and VANCOUVER, BC, Jan. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc.
BOTHELL, WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company has reached an agreement with the U.S.
MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida.
- A transitional zone between two communities containing the characteristic species of each.